At one point Insulet could have been purchased for $4+/share. Now it is north of $40+/share and still no buy-out. My guess is either management is not interested in being purchased or other larger companies do not see an acceptable return at the current valuation. In addition for companies that should be interested Medtronic, J&J etc. this technology may be disruptive to existing income streams they are trying to protect. My opinion is the Podd applications will eventually go well beyond Insulin and become the norm for most continuous injectables in hospitals, home care, etc. Should reduce the number of nurse visits and instead drug injections may be made remotely from nursing stations or even the web based upon automated vital signs / patient feedback. Less nursing care equals lower healthcare cost. So Insulet's only limitations should be the cost of the Podds (going down) and the volume (going up) they can manufacture plus regulatory approvals.